We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Longboard Stock Soars on FDA Designations for Epilepsy Drug
Read MoreHide Full Article
Shares of Longboard Pharmaceuticals gained 14% on Thursday after it announced that the FDA granted two designations — orphan drug and rare pediatric disease — to its lead pipeline drug bexicaserin for the treatment of Dravet syndrome (DS).
An orphan drug designation is granted by the FDA to the candidates developed to treat, diagnose or prevent a rare disease or condition. This designation makes the sponsor eligible to receive seven years of market exclusivity following a potential approval and tax credit for qualified clinical studies.
If the FDA grants a candidate rare pediatric disease designation, then upon potential approval of the drug, the sponsor is eligible to receive a priority review voucher (PRV). This PRV can either be used by the sponsor to obtain priority review for a different product or may even be sold by the sponsor to another to boost cash reserves.
The FDA designations come at a time when Longboard is planning to start a phase III study evaluating bexicaserin in DS patients in the coming weeks. The grant of these designations suggests that the agency recognizes the innovative approach of the LBPH drug for treating DS patients. The company’s stock price rose likely in response to this factor.
Year to date, shares of Longboard have skyrocketed 453.9% compared with the industry’s 1.3% growth.
Image Source: Zacks Investment Research
Recent Developments Responsible for the Surge in LBPH Stock
This surge in share price began at the onset of the year after management reported encouraging data from the phase Ib/IIa PACIFIC study, which evaluated bexicaserin for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). DS and Lennox-Gastaut Syndrome (LGS) are some of the many types of epilepsies that fall into the DEE group.
The PACIFIC study achieved its primary efficacy endpoint. Treatment with the drug achieved a median seizure reduction of 53.3% in the countable motor seizure frequency compared with 20.8% for those receiving placebo.
In June, management also reported positive interim data from an ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin in DEE patients. Results demonstrated sustained and durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEE patients.
The FDA had previously granted breakthrough therapy designation (BTD) to bexicaserin in June for the treatment of seizures associated with DEEs. The grant of this designation makes Longboard the first company to receive it for this indication. Drugs that receive the BTD tag receive more intensive guidance and organizational support from the agency.
In the past 60 days, estimates for Bioventus’ 2024 earnings per share (EPS) have risen from 27 cents to 40 cents. Estimates for 2025 have increased from 43 cents to 45 cents during the same period. Year to date, shares of Bioventus have surged 119.9%.
BVS’ earnings beat estimates in three of the last four quarters and missed the mark on one occasion. Bioventus delivered a four-quarter average earnings surprise of 102.86%.
In the past 60 days, estimates for Illumina’s 2024 EPS have risen from $1.84 to $3.63. Estimates for 2025 have increased from $3.22 to $4.43 during the same period. Year to date, Illumina’s shares have lost 3.5%.
Earnings of Illumina beat estimates in each of the last four quarters. Illumina delivered a four-quarter average earnings surprise of 463.46%.
In the past 60 days, estimates for Krystal Biotech’s 2024 EPS have risen from $2.09 to $2.38. Estimates for 2025 have increased from $4.33 to $7.31 during the same period. Year to date, Krystal Biotech’s shares have surged 48.7%.
Earnings of Krystal Biotech beat estimates in three of the last four quarters and missed the mark on one occasion. Krystal Biotech delivered a four-quarter average earnings surprise of 45.95%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Longboard Stock Soars on FDA Designations for Epilepsy Drug
Shares of Longboard Pharmaceuticals gained 14% on Thursday after it announced that the FDA granted two designations — orphan drug and rare pediatric disease — to its lead pipeline drug bexicaserin for the treatment of Dravet syndrome (DS).
An orphan drug designation is granted by the FDA to the candidates developed to treat, diagnose or prevent a rare disease or condition. This designation makes the sponsor eligible to receive seven years of market exclusivity following a potential approval and tax credit for qualified clinical studies.
If the FDA grants a candidate rare pediatric disease designation, then upon potential approval of the drug, the sponsor is eligible to receive a priority review voucher (PRV). This PRV can either be used by the sponsor to obtain priority review for a different product or may even be sold by the sponsor to another to boost cash reserves.
The FDA designations come at a time when Longboard is planning to start a phase III study evaluating bexicaserin in DS patients in the coming weeks. The grant of these designations suggests that the agency recognizes the innovative approach of the LBPH drug for treating DS patients. The company’s stock price rose likely in response to this factor.
Year to date, shares of Longboard have skyrocketed 453.9% compared with the industry’s 1.3% growth.
Image Source: Zacks Investment Research
Recent Developments Responsible for the Surge in LBPH Stock
This surge in share price began at the onset of the year after management reported encouraging data from the phase Ib/IIa PACIFIC study, which evaluated bexicaserin for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). DS and Lennox-Gastaut Syndrome (LGS) are some of the many types of epilepsies that fall into the DEE group.
The PACIFIC study achieved its primary efficacy endpoint. Treatment with the drug achieved a median seizure reduction of 53.3% in the countable motor seizure frequency compared with 20.8% for those receiving placebo.
In June, management also reported positive interim data from an ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin in DEE patients. Results demonstrated sustained and durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEE patients.
The FDA had previously granted breakthrough therapy designation (BTD) to bexicaserin in June for the treatment of seizures associated with DEEs. The grant of this designation makes Longboard the first company to receive it for this indication. Drugs that receive the BTD tag receive more intensive guidance and organizational support from the agency.
LBPH’s Zacks Rank
LBPH currently carries a Zacks Rank #4 (Sell).
Longboard Pharmaceuticals, Inc. Price
Longboard Pharmaceuticals, Inc. price | Longboard Pharmaceuticals, Inc. Quote
Our Key Picks Among Biotech Stocks
Some better-ranked stocks in the overall healthcare sector are Bioventus (BVS - Free Report) , Illumina (ILMN - Free Report) and Krystal Biotech (KRYS - Free Report) . Each stock presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Bioventus’ 2024 earnings per share (EPS) have risen from 27 cents to 40 cents. Estimates for 2025 have increased from 43 cents to 45 cents during the same period. Year to date, shares of Bioventus have surged 119.9%.
BVS’ earnings beat estimates in three of the last four quarters and missed the mark on one occasion. Bioventus delivered a four-quarter average earnings surprise of 102.86%.
In the past 60 days, estimates for Illumina’s 2024 EPS have risen from $1.84 to $3.63. Estimates for 2025 have increased from $3.22 to $4.43 during the same period. Year to date, Illumina’s shares have lost 3.5%.
Earnings of Illumina beat estimates in each of the last four quarters. Illumina delivered a four-quarter average earnings surprise of 463.46%.
In the past 60 days, estimates for Krystal Biotech’s 2024 EPS have risen from $2.09 to $2.38. Estimates for 2025 have increased from $4.33 to $7.31 during the same period. Year to date, Krystal Biotech’s shares have surged 48.7%.
Earnings of Krystal Biotech beat estimates in three of the last four quarters and missed the mark on one occasion. Krystal Biotech delivered a four-quarter average earnings surprise of 45.95%.